Published in Blood Weekly, February 12th, 2004
In addition, Entelos will conduct an in silico research program upon completion of the model to support clinical development and phase IV clinical trial design.
Entelos will use its proprietary PhysioLab technology to build a fully functional model in just months. The resulting systems biology platform will support a broad range of research objectives of J&JPRD as they relate to Ortho Biotech Products, L.P. and Janssen-Cilag products Procrit and Eprex.
PhysioLab platforms encompass dynamic,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-02-12)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.